Organisation paid for research Program year 2025 Source: CMS Open Payments

Emerson Clinical Research Inst

Neither a doctor nor a teaching hospital

Research payments

$324,081

102 payments

Through program year 2025, Emerson Clinical Research Inst is reported as receiving $324,081 in research payments, across 102 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $18,278 3
2024 Research $132,062 48
2023 Research $122,897 45
2022 Research $50,844 6

Breakdown

Who paid Research payments · program years 2022–2025
  1. Moderna TX, Inc. $219,390 85 payments
  2. Genentech, Inc. $43,770 3 payments
  3. Sumitomo Pharma America, Inc. $35,569 8 payments
  4. Eli Lilly and Company $16,768 1 payment
  5. Ultragenyx Pharmaceutical Inc. $6,028 1 payment
  6. AbbVie, Inc. $2,486 3 payments
  7. Pfizer Inc. $70 1 payment
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $219,390 85 payments
  2. Faricimab for Under Represented Patients With Dme $43,770 3 payments
  3. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $35,569 8 payments
  4. A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 MG and 4.5 MG in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus $16,768 1 payment
  5. Dtx301-Cl102 $6,028 1 payment
  6. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) $1,440 1 payment
  7. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $806 1 payment
  8. Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $240 1 payment
  9. A Master Phase 123 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children $70 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record